TrialDaily
The drug-pipeline briefing, now part of ScholarDaily.
TrialDaily is now part of ScholarDaily. Its briefing continues inside ScholarDaily, where one subscription unlocks every briefing. This page, its privacy policy, and its terms stay online for reference.
TrialDaily is now part of ScholarDaily. Its weekday briefing, which turns the day's clinical-trial registrations and FDA activity into readable briefs with a link back to the ClinicalTrials.gov or FDA record behind every item, continues as one of seven official-source briefings in ScholarDaily, where one subscription unlocks them all. TrialDaily is no longer offered as a separate app.
Features
One curated briefing every weekday, led by the day's most consequential move.
Phase 2/3 trial launches, results postings, FDA approvals, and drug recalls, drawn from ClinicalTrials.gov, openFDA, and the FDA newsroom.
Plain-language briefs — what changed, the particulars, why it matters, what to watch.
The verifiable facts alongside every item: sponsor, phase, enrollment, endpoints, application number.
A direct link to the primary record on ClinicalTrials.gov or FDA.gov on every single item.
Read in English or 简体中文.
Read inside ScholarDaily, with its archive and search, alongside six other official-source briefings under one subscription.
Key questions
What is TrialDaily?
TrialDaily is now part of ScholarDaily. Its weekday briefing, which turns the day's clinical-trial registrations and FDA activity into readable briefs with a link back to the ClinicalTrials.gov or FDA record behind every item, continues as one of seven official-source briefings in ScholarDaily, where one subscription unlocks them all. TrialDaily is no longer offered as a separate app. Core workflow: One curated briefing every weekday, led by the day's most consequential move.
Which platforms does TrialDaily support?
TrialDaily supports iOS.
How does TrialDaily handle data?
TrialDaily stores a few preferences on your device — your chosen language (English or 简体中文), your subscription state, and a small cache of the most recent briefing so it loads instantly when you reopen the app. You can clear these from Settings → Reset inside the app, or by deleting the app. There is no TrialDaily account, no profile, and no per-reader record on the server; the backend serves the same briefing to everyone. TrialDaily collects nothing about you, stores nothing about you, and sells nothing about you. There is no advertising SDK, no analytics SDK, no crash reporter, and no telemetry of any kind. Requests to the server carry no identifier tied to you, and IP addresses are not logged against the content you read or retained after a request completes. Subscription receipts are sent to Apple for validation. Source material comes from public U.S. government datasets; following a source link opens that record in your browser and is governed by those sites' own policies.